Imiquimod combined with photodynamic therapy for hypertrophic scars: immune response and prognosis

doi:10.12307/2023.095

Abstract

Abstract: BACKGROUND: Hyperplasia scar is caused by dermal fibrosis due to fibroblast proliferation, uncontrolled growth and excessive collagen deposition. Both photodynamic therapy and imiquimod can inhibit fibroplasia. Imiquimod can further increase cell apoptosis and reduce the proliferation activity of fibroblasts by activating the immune response system.
OBJECTIVE: To study the effect of imiquimod combined with photodynamic therapy on the immune response and prognosis of patients with hypertrophic scars.
METHODS: A total of 110 patients with hypertrophic scars admitted to Shijiazhuang People’s Hospital from December 2017 to March 2020 were enrolled and randomly divided into a control group and a study group, with 55 patients in each group. Patients in the control group were given photodynamic therapy (every 10 days, four times in total) and those in the study group were treated with imiquimod cream (once a day for continuous 3 months) based on photodynamic therapy. The Vancouver Scar Scale was used to evaluate scar changes on day 2 after treatment. Clinical efficacy was evaluated and compared between the two groups of patients. The serum levels of interferon-γ, tumor necrosis factor-α, interleukin-2 and interleukin-6 were determined by enzyme-linked immunosorbent assay before and after treatment. The immunoturbidimetric method was used to determine the serum levels of IgA, IgG, and IgM in the two groups of patients. The occurrence of adverse reactions was recorded in the two groups.
RESULTS AND CONCLUSION: (1) Before treatment, there was no significant difference in softness, thickness, blood vessel distribution, and color score between the two groups (P > 0.05). After treatment, the softness, thickness, blood vessel distribution and color scores of the two groups were significantly reduced, and the above-mentioned scores in the study group were significantly lower than those in the control group (P < 0.001). (2) The clinical response rate of the study group was 96%, which was significantly higher than that of the control group (78%; P < 0.05). (3) Before treatment, there were no significant differences in the serum levels of interferon-γ, tumor necrosis factor-α, interleukin-2 and interleukin-6 between the two groups (P > 0.05). After treatment, the serum levels of interferon-γ, tumor necrosis factor-α, interleukin-2 and interleukin-6 were significantly reduced in the two groups, and the levels of the above-mentioned indicators in the study group were significantly lower than those in the control group (P < 0.001). (4) Before treatment, there was no significant difference in serum IgA, IgG and IgM levels between the two groups (P > 0.05). After treatment, the serum levels of IgA, IgG and IgM increased significantly in the two groups, and the serum levels of IgA, IgG and IgM in the study group were significantly higher than those in the control group (P < 0.05). (5) The total adverse reaction rate in the control group was 13%, which was significantly higher than that of the study group (2%; P < 0.05). (6) To conclude, imiquimod combined with photodynamic therapy has a good effect in the treatment of hypertrophic scars, which can significantly reduce inflammatory responses, improve immune function, and have fewer adverse reactions in such patients.

Key words: imiquimod, photodynamic therapy, hypertrophic scar, inflammatory response, immune function, immune response

CLC Number:

Lu Huixiu, Cao Haiyu, Lou Dan, Li Jianying, Liu Hongyuan, Sun Jing. Imiquimod combined with photodynamic therapy for hypertrophic scars: immune response and prognosis[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(5): 690-694.

Figures/Tables 7

References

[1] LIMANDJAJA GC, NIESSEN FB, SCHEPER RJ, et al. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. Exp Dermatol. 2021;30:146-161.
[2] TAPKING C, PRASAI A, BRANSKI LK. Are hypertrophic scars and keloids the same? Br J Dermatol. 2019;182(4):832-833.
[3] 姚翠英,陈芳.炎症和纤维标志物在痤疮增生性瘢痕形成中的表达[J]. 基因组学与应用生物学,2020,39(6):450-456.
[4] 杨丽, 李娜, 程静, 等. 脉冲染料激光用于烧伤后增生性瘢痕的最佳治疗间隔的前瞻性随机对照临床研究[J]. 中华烧伤杂志,2020, 37(1):57-63.
[5] 雷颖, 彭诗绮, 陈红阳, 等. 点阵激光联合脉冲染料激光加多点微量注射曲安奈德对兔耳增生性瘢痕的影响[J]. 中华整形外科杂志, 2020,36(10):1128-1138.
[6] 尹光文, 刘聪, 王小云,等. 氨基酮戊酸-光动力疗法对尖锐湿疣组织中血管内皮生长因子和增殖细胞核抗原表达的影响[J]. 中华皮肤科杂志,2020,53(1):48-50.
[7] LAN J, DU H, LI Y, et al. Dextran-based acitretin nanoparticle ameliorates imiquimod-induced psoriasis-like skin inflammation. J Invest Dermatol. 2020;140(7):S1.
[8] KIM SG, KIM EY, KIM YJ, et al. The Efficacy and safety of abla-tive fractional resurfacing using a 2, 940-Nm Er: YAG laser for traumatic scars in the early posttraumatic period. Arch Plast Surg. 2012;39(3): 232-237.
[8] ELREFAIE AM, SALEM RM, FAHEEM MH. High-resolution ultrasound for keloids and hypertrophic scar assessment. Lasers Med Sci. 2020;35: 379-385.
[9] MIGITA H, RIKIMARU H, RIKIMARU-NISHI Y, et al. Analysis of Scars and Keloids by Focused Ion Beam/Scanning Electron Microscopy: Distinguishing Between Hypertrophic Scars and Keloids. Ann Plastic Surg. 2020;84(4):379-384.
[10] KHAN FA, DRUCKER NA, LARSON S, et al. Pediatric earlobe keloids: Outcomes and patterns of recurrence – Science Direct. J Pediatr Surg. 2020;55(3):461-464.
[11] WANG X, GU C, SHANG F, et al. Inhibitory Effect of the LY2109761 on the Development of Human Keloid Fibroblasts. Analyt Cell Pathol (Amsterdam). 2021;2021:8883427.
[12] 程梦星, 邱丽华. 光动力治疗在宫颈疾病中的应用[J]. 现代妇产科进展,2020,29(5):79-81.
[13] 谢春晖, 高欣欣, 孟祥龙, 等. 早期应用序贯激光治疗烧伤患儿增生性瘢痕的效果分析[J]. 中华烧伤杂志,2021,37(4):327-332.
[14] 黄振, 陈烨, 王朋, 等. 二氧化碳点阵激光联合自体脂肪注射治疗烧伤后增生性瘢痕效果的前瞻性平行对照临床研究[J]. 中华烧伤杂志,2020,37(1):49-56.
[15] PETTERSSON CM, BROSTRÖM H, HUMBLOT P, et al. Topical treatment of equine sarcoids with imiquimod 5% cream or Sanguinaria canadensis and zinc chloride - an open prospective study. Vet Dermatol. 2020;31: 471.
[16] 青玉,巴图德力根,韩志强,等. 咪喹莫特诱导小鼠银屑病样动物模型的建立与评价[J]. 中国临床药理学杂志,2019,35(1):73-75.
[17] KORPPI M, TERSJRVI J, LAUHKONEN E, et al. Toll‐like receptor 4 polymorphisms were associated with low serum pro‐inflammatory cytokines in BCG osteitis survivors. Acta Paediatrica. 2020;109(7): 1417-1422.
[18] SHAHID H, SHAHZAD M, SHABBIR A, et al. Immunomodulatory and Anti-Inflammatory Potential of Curcumin for the Treatment of Allergic Asthma: Effects on Expression Levels of Pro-inflammatory Cytokines and Aquaporins. Inflammation. 2019;42(6):2037-2047.
[19] FAN Y, YANG L, WEI Q, et al. Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. Asian J Androl. 2019;21(4):393-399.
[20] LIM E, JEON JY. Congenital adrenal hyperplasia presenting as pelvic inflammatory disease in a phenotypic male: A case report. Medicine. 2020;99(2):e18387.
[21] 李燕姿,武咪,平宝华,等. 抑制吲哚胺2,3双加氧酶活性可增强Toll样受体7激动剂咪喹莫特在胃癌中的抗肿瘤作用[J]. 西安交通大学学报(医学版),2020,41(5):696-700,723.
[22] 林康,苏海燕,虞庆,等. 苏拉明通过抑制纤维增生和炎症反应减轻小鼠的瘢痕增生[J]. 中国病理生理杂志,2019,35(11):2070-2077.
[23] 张思敏,亓发芝. 巨噬细胞极化在增生性瘢痕和瘢痕疙瘩中的作用[J]. 中国免疫学杂志,2019,35(5):639-642.
[24] 苏秦, 高进, 付俊鲜,等. 血流动力学指标和IL-6在脓毒症肾损伤患儿中的表达及其与免疫指标的相关性[J]. 中国免疫学杂志,2020, 36(10):1235-1239.
[25] ANGELOPOULOU A, ALEXANDRIS N, KONSTANTINOU E, et al. Imiquimod-A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environmental Res. 2020;188:109858.
[26] SCIULLO PD, MENAY F, COCOZZA F, et al. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma. Clin Immunol. 2019;203:154-161.